Immunotherapy News and Research RSS Feed - Immunotherapy News and Research

Immunotherapy is the concept of using the immune system to treat disease, for example, developing a vaccine against cancer. Immunotherapy may also refer to the therapy of diseases caused by the immune system, allergies for example.
Study provides vital information regarding four diagnostic PD-L1 assays

Study provides vital information regarding four diagnostic PD-L1 assays

A pre-competitive consortia of pharmaceutical companies, diagnostic companies, and academic associations, including the International Association for the Study of Lung Cancer, announced phase I results of the "BLUEPRINT PD-L1 IHC ASSAY COMPARISON PROJECT" at the Annual Meeting of the American Association for Cancer Research on April 19. [More]
Bim protein may hold clue for immunotherapy response in metastatic melanoma patients

Bim protein may hold clue for immunotherapy response in metastatic melanoma patients

A protein called Bim may hold the clue to which patients may be successful on immunotherapy for metastatic melanoma, according to the results of a study by Mayo Clinic researchers led by senior author Haidong Dong, M.D., Ph.D., and published online in the May 5 edition of JCI Insight. [More]
Duke scientists develop human-derived antibody that preferentially attacks cancer cells

Duke scientists develop human-derived antibody that preferentially attacks cancer cells

A research team from Duke Health has developed an antibody from the body's own immune system that preferentially attacks cancer cells. [More]
Experimental drug ozanimod moderately effective in treatment of ulcerative colitis

Experimental drug ozanimod moderately effective in treatment of ulcerative colitis

Researchers at University of California San Diego School of Medicine have shown that ozanimod (RPC1063), a novel drug molecule, is moderately effective in the treatment of ulcerative colitis. Results of the Phase II clinical trial will appear in the May 5 issue of the New England Journal of Medicine. [More]
NSCLC MAGE-A3 immunotherapy development halted

NSCLC MAGE-A3 immunotherapy development halted

Disease-free survival is not prolonged with adjuvant MAGE-A3 immunotherapy in patients with surgically resected non-small-cell lung cancer, according to a placebo-controlled trial. [More]
Cerebellar not cerebral atrophy predicts poor anti-NMDAR encephalitis outcome

Cerebellar not cerebral atrophy predicts poor anti-NMDAR encephalitis outcome

Diffuse cerebral atrophy in patients with anti-N-methyl-D-aspartate receptor encephalitis does not necessarily mean irreversible brain damage, whereas progressive cerebellar atrophy may indicate a poor long-term prognosis, researchers report. [More]
Ibrutinib shows added benefit for refractory mantle cell lymphoma patients

Ibrutinib shows added benefit for refractory mantle cell lymphoma patients

Ibrutinib is a drug for the treatment of rare diseases. It has been approved for the treatment of adults with chronic lymphocytic leukaemia (CLL) or with relapsed or refractory mantle cell lymphoma (MCL) since 2014, and since 2015 also for the treatment of adults with Waldenström macroglobulinaemia. Regarding the treatment of patients with CLL or MCL, the Federal Joint Committee (G-BA) already conducted a benefit assessment and made a decision in 2015. [More]
Addition of L19-IL2 can increase radiation therapy-induced immune response against tumours

Addition of L19-IL2 can increase radiation therapy-induced immune response against tumours

Radiation therapy not only kills cancer cells, but also helps to activate the immune system against their future proliferation. However, this immune response is often not strong enough to be able to cure tumours, and even when it is, its effect is limited to the area that has been irradiated. [More]
Janssen gets positive CHMP opinion for IMBRUVICA (ibrutinib) to treat patients with previously untreated CLL

Janssen gets positive CHMP opinion for IMBRUVICA (ibrutinib) to treat patients with previously untreated CLL

Janssen-Cilag International NV today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a Positive Opinion, recommending broadening the existing marketing authorisation for ibrutinib as a single agent for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). [More]
Experimental therapy has over 90% remission rate for advanced leukemia patients

Experimental therapy has over 90% remission rate for advanced leukemia patients

Twenty-seven of 29 patients with an advanced type of leukemia that had proved resistant to multiple other forms of therapy went into remission after their T cells (disease-fighting immune cells) were genetically engineered to fight their cancers. [More]
HDM SLIT tablet can reduce risk of moderate or severe asthma exacerbation

HDM SLIT tablet can reduce risk of moderate or severe asthma exacerbation

The addition of a house dust mite (HDM) sublingual allergen immunotherapy (SLIT) tablet to maintenance medications improved time to first moderate or severe asthma exacerbation during a period of inhaled corticosteroid (ICS) reduction among adults with HDM allergy-related asthma not well controlled by ICS, according to a study appearing in the April 26 issue of JAMA. [More]
Scientists uncover molecular identity of previously unknown Glima molecule in Type 1 diabetes

Scientists uncover molecular identity of previously unknown Glima molecule in Type 1 diabetes

Scientists have solved a decades-old medical mystery by finally identifying a previously unknown molecule which is attacked by the immune system in people with Type 1 diabetes. [More]
Study shows cancer cell death via necroptosis can drive pancreatic tumor growth

Study shows cancer cell death via necroptosis can drive pancreatic tumor growth

The most aggressive form of pancreatic cancer - often described as one of the hardest malignancies to diagnose and treat -- thrives in the presence of neighboring tumor cells undergoing a particular form of "orchestrated cell death." This is according to a major study recently published in the journal Nature. [More]
Scientists examine PD-1-expressing regulatory T cells in aggressive brain cancer

Scientists examine PD-1-expressing regulatory T cells in aggressive brain cancer

Immunotherapy represents an exciting advance in cancer treatment that harnesses the immune system to seek and destroy cancer cells. [More]
Study paves way for refining antibody-based cancer immunotherapy

Study paves way for refining antibody-based cancer immunotherapy

A study coordinated by the Malmberg Laboratory at Oslo University Hospital/University of Oslo and the Karolinska Institute, published in Cell Reports, reveals a molecule that trigger cancer recognition in natural killer (NK) cells. [More]
Better way to model human immune system

Better way to model human immune system

Scientists at the University of Minnesota have developed a new way to study mice that better mimics the immune system of adult humans and which could significantly improve ways to test potential therapeutics. Published online today in the journal Nature, the researchers describe the limitations of laboratory mice for immunology research and reveal the benefits of what they are calling "dirty mice." [More]
Proteins can be used as targets to deliver drugs into stressed cancer cells

Proteins can be used as targets to deliver drugs into stressed cancer cells

Targeted missiles that can enter cancer cells and deliver lethal cell toxins without harming surrounding healthy tissue. This has been a long-standing vision in cancer research, but it has proved difficult to accomplish. A research group at Lund University in Sweden has now taken some crucial steps in this direction. [More]
Immunotherapy drug pembrolizumab shrinks tumors in patients with Merkel cell carcinoma

Immunotherapy drug pembrolizumab shrinks tumors in patients with Merkel cell carcinoma

In a clinical trial of the immunotherapy drug pembrolizumab, half of 25 patients with a rare type of virus-linked skin cancer called Merkel cell carcinoma experienced substantial tumor shrinkage lasting nearly three times as long, on average, than with conventional chemotherapy. [More]
Nivolumab drug shows survival benefit in phase III trial of patients with head and neck cancer

Nivolumab drug shows survival benefit in phase III trial of patients with head and neck cancer

The immunotherapy drug nivolumab has become the first to show a survival benefit in head and neck cancer, after a major international trial found that it was more effective than standard chemotherapy. [More]
Penn researchers report results of CAR therapy trial in brain cancer patients

Penn researchers report results of CAR therapy trial in brain cancer patients

Immune cells engineered to seek out and attack a type of deadly brain cancer known as glioblastoma (GBM) were found to have an acceptable safety profile and successfully migrate to and infiltrate tumors, researchers from Penn Medicine and Harvard University reported at the AACR Annual Meeting 2016. [More]
Advertisement
Advertisement